Your session is about to expire
← Back to Search
Tau Imaging with F-18 AV 1451 for Progressive Supranuclear Palsy
N/A
Recruiting
Led By Keith Josephs, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
Study Summary
This trial will study tau burden in the brains of PSP patients to learn more about the disease.
Who is the study for?
This trial is for adults over 35 with Progressive Supranuclear Palsy (PSP) symptoms and a diagnosis of possible or probable PSP. Participants need an informant to provide additional information about their functioning. Exclusions include pregnancy, other neurodegenerative diseases, conditions that mimic PSP symptoms, certain genetic conditions increasing cancer risk, contraindications to MRI, severe claustrophobia, and unstable medical conditions.Check my eligibility
What is being tested?
The study tests the imaging agent F-18 AV 1451 to measure tau protein accumulation in the brain of patients with PSP. It aims to understand the overall burden of tau in these patients using advanced imaging techniques.See study design
What are the potential side effects?
As this trial involves an imaging procedure rather than a drug treatment, side effects are minimal but may include discomfort from lying still during scanning and potential allergic reactions to the tracer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with Progressive Supranuclear Palsy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The investigators will be looking at the amount of Tau protein in the brain of patients with PSP.
Secondary outcome measures
Rates of change in tau-PET burden over time.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tau PET Scan, F-18 AV 1451Experimental Treatment1 Intervention
All subjects will received a Tau PET scan.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,207 Previous Clinical Trials
3,765,820 Total Patients Enrolled
Keith Josephs, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
47 Total Patients Enrolled
Jennifer Whitwell, PhDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
77 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have any other neurodegenerative diseases besides possible PSP.I do not have genetic conditions like Cowden, Lynch syndrome, or Down's syndrome.I do not have illnesses like brain injury, encephalitis, strokes, or developmental syndromes.I am over 35 and my PSP symptoms are getting worse slowly.I have been diagnosed with Progressive Supranuclear Palsy.I cannot have an MRI due to metal implants, severe claustrophobia, or certain medical conditions.I am not pregnant or breastfeeding.
Research Study Groups:
This trial has the following groups:- Group 1: Tau PET Scan, F-18 AV 1451
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants have been recruited for this clinical trial?
"Affirmative. The clinicaltrial.gov website exhibits that this experiment is still in progress and actively looking for participants since it was posted on November 1st 2015, with the last edit being done on November 4th 2022. It requires 332 volunteers from one medical facility to take part."
Answered by AI
Is recruitment for this research endeavor still available?
"Clinicaltrials.gov indicates that the trial is currently accepting patients; it was first posted on November 1st 2015 and most recently updated on the 4th of November 2022."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger